MiStent® bioabsorbable
polymer stents help
improve outcomes

Sirolimus in crystalline form
provides controlled and
sustained drug elution in tissue

Product available
through key
distribution partners

Transforming medical devices for improved patient outcomes
TECHNOLOGY

Our proprietary technology utilizes supercritical fluids, which allow for prolonged therapeutic drug dosing after polymer absorption.

Read more...
PRODUCTS

Our products are designed to make clinically meaningful improvements in patient outcomes, and are available in select countries around the world.

Read more...
CLINICAL TRIALS

Our ongoing clinical trials are designed to confirm the effectiveness of our technology in interventional cardiology.

Read more...
LATEST NEWS

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

Click to see full press release
Dessolve III 12-Month Data Discussed

See an interview with Prof. R. J. de Winter, M.D., Ph.D. following his late-breaking trial presentation at EuroPCR 2017

Watch video ...
What's Causing the MiStent Advantage vs. Xience in an OCT Sub-study? Experts Weigh In.

EuroPCR 2017 Panelists: P. W. Serruys, E. Edelman, R.J. de Winter, K. Milewski, and G. Sardella

Watch video . . .